First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. - Wikidata - wikimedia - TriplyDB

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

http://www.wikidata.org/entity/Q42577721

about

Neonatal clinical pharmacology First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model Clinical pharmacology in neonates: small size, huge variability Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development.Paediatric pharmacokinetics: key considerations.Predicting pediatric age-matched weight and body mass index Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.Pharmacokinetic studies in infants using minimal-risk study designs Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System.The influence of rapid growth in broilers on florfenicol pharmacokinetics - allometric modelling of the pharmacokinetic and haemodynamic parameters.Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

P2860

Q26992019-E7F8A00D-6BA2-4835-ACF6-BD39BDC479F0 Q30844731-5F1AFFB9-7E11-408C-91D2-0CD040FA2359 Q31033069-D3A6712F-E473-4DC5-B948-87897CAEC8EC Q33574126-340F3F2F-1265-4BE6-BA3B-BE2AB815DA68 Q33950874-56833406-0C92-4454-B922-2944FB7C7546 Q34449605-A2DE4C2E-AE37-4A75-B682-79776B598925 Q35135940-868F6B31-CD2E-40CA-8ABB-0722D684CAB0 Q35318223-B8207FD3-62A2-4E21-8E2F-A24640A0B7FE Q36072504-864EE2B7-F6BA-4651-8669-C8FC13C3DD11 Q36438116-94A05FA5-9378-44D0-99F2-2F41BF072D14 Q36987975-74577276-D69B-4057-B787-78D3414EBB20 Q37279407-7E3760FC-C74B-4164-9A99-8D28F52CC874 Q37470692-18F357E8-5BB9-49AD-9B08-A2628C198AD5 Q38458340-FFF31508-ED97-4149-A4E6-FBC689526A4F Q38857191-F2B2D18E-DDAD-4F70-BD1B-2A5BD6EF8C61 Q39508318-3A67D338-71F6-4F34-936F-D6CD718E539E Q42907122-82256199-093A-4D14-A02C-983599DFD894 Q50930805-EFA4D580-F3FC-40F0-A979-3D8E3FE95A08 Q51099069-35CFC13B-B8B8-4B96-A8AB-5F6CCA1861AB Q53285942-732A3A8B-17D5-4D5E-807A-AD5CF83A5C21

P2860

First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.

http://www.wikidata.org/entity/Q42577721

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

First dose in children: physio ...... n paediatric drug development.

@en

First dose in children: physio ...... n paediatric drug development.

@nl

type

label

First dose in children: physio ...... n paediatric drug development.

@en

First dose in children: physio ...... n paediatric drug development.

@nl

prefLabel

First dose in children: physio ...... n paediatric drug development.

@en

First dose in children: physio ...... n paediatric drug development.

@nl

P1433

Q42577721-F3D77ED9-2482-4B2E-99EB-9EFF1A036D02

P1476

Q42577721-3DBBBCCB-F99C-4202-B99A-41315A8A9C2D

P2093

Q42577721-4C367F5E-24C4-46AC-8628-E0BEF72EEC9D

Q42577721-4D6A6384-63B7-449F-80F7-DA089E8FB8D8

Q42577721-5E27E277-8C19-41C4-846F-18193254B790

Q42577721-60CCCCD6-DE8C-4FB2-94B9-2036F40474F6

Q42577721-B1AABAD7-F9D2-4336-B914-5A668B5530C9

Q42577721-EFDDD47C-8193-4099-9610-8DF8AE8C1D0B

P2860

Q42577721-0FC720C9-C214-44C8-8EDE-F4F4B0BCF8D6

Q42577721-2CAF832C-20EE-4B94-8EC5-CD67C58968F6

Q42577721-668A5277-B627-40D8-980F-3B98912C845B

Q42577721-6ACF953F-C608-4478-8B68-19E2DA49594F

Q42577721-6F915C2E-8441-47E9-B7F2-377E8B5B2490

Q42577721-7809ED21-BE39-445E-B006-449504F3A932

Q42577721-7F30865C-37C7-4F70-9B03-16F388F5878B

Q42577721-8007DEE4-5FBB-4800-9BAD-14324D69B95B

Q42577721-AB9793CB-6766-46FA-A9A4-4DDA3A03D65E

Q42577721-ADDDB78D-3000-41A4-B7B9-A2DCDBD89EBF

P2888

Q42577721-AEE12FE2-7ED0-405A-83CE-A676F087CE88

P304

Q42577721-8856ECCA-D3FB-4AE7-AC73-D729E82EE4F3

P31

Q42577721-B5FF982B-2F29-43CD-92B0-659BD0EE3CDB

P356

Q42577721-1B67A3F2-A937-4C78-913B-354B52B4CB4A

P433

Q42577721-A7D9A0B0-BCBC-416A-9345-96DE385ED7DF

P478

Q42577721-7476659E-AF07-49CA-B4A1-B730CCC32975

P577

Q42577721-FB052521-48FE-49F6-B7C5-F6983A5D73D5

P5875

Q42577721-5DF24FCE-4FA0-452C-AA1F-FF224EB9A9DC

P698

Q42577721-980883C8-2CAB-4784-80CC-196FA96AC2F3

P932

Q42577721-4AA8D971-93CC-4FF3-B63C-4D3C816CF58F

P356

S10928-012-9241-9

P1433

Journal of Pharmacokinetics and Pharmacodynamics

P1476

First dose in children: physio ...... n paediatric drug development.

@en

P2093

Ashley Strougo

http://www.w3.org/2001/XMLSchema#string

Ashraf Yassen

http://www.w3.org/2001/XMLSchema#string

Jan Freijer

http://www.w3.org/2001/XMLSchema#string

Meindert Danhof

http://www.w3.org/2001/XMLSchema#string

Stefan Willmann

http://www.w3.org/2001/XMLSchema#string

Thomas Eissing

http://www.w3.org/2001/XMLSchema#string

P2860

A general model for the origin of allometric scaling laws in biology

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Clinical pharmacokinetics of morphine.

Whole body pharmacokinetic models.

Mechanism-based concepts of size and maturity in pharmacokinetics.

Facilitation of drug evaluation in children by population methods and modelling.

Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial.

Paracetamol metabolism and related genetic differences.

Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines.

Morphine glucuronidation in preterm neonates, infants and children younger than 3 years.

P2888

s10928-012-9241-9

P304

195-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-012-9241-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221811755

http://www.w3.org/2001/XMLSchema#string

P698

22311388

http://www.w3.org/2001/XMLSchema#string

P932

3306781

http://www.w3.org/2001/XMLSchema#string